Boston Scientific (NYSE:BSX) said today that it built out its biliary offering with the acquisition of endoscope maker EMcision for an undisclosed amount.
London- and Montreal-based EMcision makes the Habib EndoHPB probe, which is designed to coagulate tissue in the gastrointestinal tract in treating pancreaticobiliary cancers. Marlborough, Mass.-based Boston Scientific said the probe has 510(k) clearance from the FDA and CE Mark approval in the European Union.
“As we continue to search for ways to treat pancreaticobiliary cancers, we also seek to improve the quality of life for patients living with a cancer diagnosis today,” endoscopy president Art Butcher said in prepared remarks. “We are committed to exploring innovative options to help increase the chance of early diagnosis, improve treatment and advance the ability to remove cancers located in challenging areas of the gastrointestinal tract.”
The deal is not expected to affect earnings per share this year, Boston Scientific said.
In November 2016 the company closed its $210 million buyout of EndoChoice and its line of devices for treating gastrointestinal disease.
